Journal of Cancer Treatment and Research

Special Issue

Modern Multidisciplinary Approach to Management of Stage IV Breast Cancer Patients

  • Submission Deadline: Feb. 25, 2020
  • Status: Submission Closed
  • Lead Guest Editor: Kelsey Larson
About This Special Issue
Article selection would focus on multidisciplinary spectrum of care for patients with stage IV breast cancer. Topics may be submitted by surgeons, medical oncologists, radiation oncologists, geneticists, palliative care, pain management, survivorship, basic and translational science researchers, etc. Papers that focus on challenging current concepts in care and promoting more modern approaches to these patients are preferred.

Aims and Scope:

  1. Breast Cancer
  2. Stage IV
  3. Metastatic
  4. Multidisciplinary
  5. Surgery
  6. Medical oncology
  7. Radiation oncology
Lead Guest Editor
  • Kelsey Larson

    University of Kansas, Kansas, United States

Guest Editors
  • Priya Jadeja

    Summit Medical Group, Livingston, United States

  • Megan Kruse

    Cleveland Clinic, Cleveland, United States

  • Betty Fan

    Cleveland Clinic, Beth Israel Deaconness, Cleveland, United States

  • Cheng Peng

    Shanghai Jiao Tong University School of Medicine, Shanghai, China

Published Articles
  • Impact of Germline BRCA Mutation Status on Survival in Women with Metastatic Triple Negative Breast Cancer

    Kelsey E. Larson , Yen Y. Wang , Karissa Finke , Rachel Yoder , Kelsey Schwensen , Anne P. O’Dea , Qamar Khan , Lauren Nye , Jaimie Heldstab , Andrew K. Godwin , Bruce F. Kimler , Priyanka Sharma

    Issue: Volume 7, Issue 4, December 2019
    Pages: 81-86
    Received: Oct. 23, 2019
    Accepted: Dec. 07, 2019
    Published: Dec. 31, 2019
    DOI: 10.11648/j.jctr.20190704.13
    Abstract: Purpose: To investigate the association between germline deleterious BRCA1 or BRCA2 mutations (gBRCA+) and overall survival (OS) for patients with metastatic triple negative breast cancer (mTNBC). Methods: An IRB approved prospective multisite registry enrolling stage I-IV TNBC patients from 2011-2018 was utilized. Demographics, treatments, genetic... Show More